Evidence map›Paper›PMID 32771650›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.

Julia J Scialla, Jessica Kendrick, Jaime Uribarri, Csaba P Kovesdy, Orlando M Gutiérrez, Elizabeth Yakes Jimenez, Holly J Kramer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Phosphate and Cellular Senescence.Advances in experimental medicine and biology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Julia J SciallaDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA; Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA. Electronic address: jscialla@virginia.edu.
Jessica KendrickDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Jaime UribarriDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Csaba P KovesdyDepartment of Medicine, University of Tennessee Health Science Center and Memphis Veterans Affairs Medical Center, Memphis, TN.
Orlando M GutiérrezDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL.
Elizabeth Yakes JimenezDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico; Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico; Nutrition Research Network, Academy of Nutrition and Dietetics, Chicago, IL.
Holly J KramerDepartment of Medicine, Loyola University Chicago, Maywood, IL; Department of Public Health Sciences, Loyola University Chicago, Maywood, IL.
Icahn School of Medicine at Mount Sinai · USLoyola University Chicago · USResearch Network (United States) · USUniversity of Alabama at Birmingham · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Tennessee Health Science Center · USUniversity of Virginia · US

Funding

Bicarbonate Administration In CKDR01HL132868 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KENDRICK, JESSICA B · 2017 to 2020
$1.7M
Integrated Mineral Metabolism Treatment Strategies in Patients on DialysisR01DK111952 · NIDDK · UNIVERSITY OF VIRGINIA · PI SCIALLA, JULIA J · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL132868NIDDK NIH HHS R01 DK111952
6 · The paper itself

Abstract

Phosphate binders are among the most common medications prescribed to patients with kidney failure receiving dialysis and are often used in advanced chronic kidney disease (CKD). In patients with CKD glomerular filtration rate category 3a (G3a) or worse, including those with kidney failure who are receiving dialysis, clinical practice guidelines suggest "lowering elevated phosphate levels towards the normal range" with possible strategies including dietary phosphate restriction or use of binders. Additionally, guidelines suggest restricting the use of oral elemental calcium often contained in phosphate binders. Nutrition guidelines in CKD suggest<800-1,000mg of calcium daily, whereas CKD bone and mineral disorder guidelines do not provide clear targets, but<1,500mg in maintenance dialysis patients has been previously recommended. Many different classes of phosphate binders are now available and clinical trials have not definitively demonstrated the superiority of any class of phosphate binders over another with regard to clinical outcomes. Use of phosphate binders contributes substantially to patients' pill burden and out-of-pocket costs, and many have side effects. This has led to uncertainty regarding the use and best choice of phosphate binders for patients with CKD or kidney failure. In this controversies perspective, we discuss the evidence base around binder use in CKD and kidney failure with a focus on comparisons of available binders.

Indexed as

Chelating AgentsHyperphosphatemiaPatient Care ManagementRenal Insufficiency, ChronicCalciumClinical Trials as TopicHumansPhosphatesRenal DialysisCalciumChelating AgentsPhosphatescalciumcalcium acetatechronic kidney disease (CKD)dialysisferric citratehemodialysishypercalcemiakidney failurelanthanum carbonatemedical nutrition therapy (MNT)mortalitynon–calcium-based binderPhosphate binderphosphorussevelamersucroferric oxyhydroxide

Identifiers

PMID32771650
PMCPMC8109252
OpenAlexW3047344708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.